Circulating phthalates during critical illness in children are associated with long-term attention deficit: a study of a development and a validation cohort

S Verstraete, I Vanhorebeek, A Covaci, F Güiza, G Malarvannan, P G Jorens, G Van den Berghe, S Verstraete, I Vanhorebeek, A Covaci, F Güiza, G Malarvannan, P G Jorens, G Van den Berghe

Abstract

Purpose: Environmental phthalate exposure has been associated with attention deficit disorders in children. We hypothesized that in children treated in the pediatric intensive care unit (PICU), circulating phthalates leaching from indwelling medical devices contribute to their long-term attention deficit.

Methods: Circulating plasma concentrations of di(2-ethylhexyl)phthalate (DEHP) metabolites were quantified in 100 healthy children and 449 children who had been treated in PICU and were neurocognitively tested 4 years later. In a development patient cohort (N = 228), a multivariable bootstrap study identified stable thresholds of exposure to circulating DEHP metabolites above which there was an independent association with worse neurocognitive outcome. Subsequently, in a second patient cohort (N = 221), the observed independent associations were validated.

Results: Plasma concentrations of DEHP metabolites, which were virtually undetectable [0.029 (0.027-0.031) µmol/l] in healthy children, were 4.41 (3.76-5.06) µmol/l in critically ill children upon PICU admission (P < 0.001). Plasma DEHP metabolite concentrations decreased rapidly but remained 18 times higher until PICU discharge (P < 0.001). After adjusting for baseline risk factors and duration of PICU stay, and further for PICU complications and treatments, exceeding the potentially harmful threshold for exposure to circulating DEHP metabolites was independently associated with the attention deficit (all P ≤ 0.008) and impaired motor coordination (all P ≤ 0.02). The association with the attention deficit was confirmed in the validation cohort (all P ≤ 0.01). This phthalate exposure effect explained half of the attention deficit in post-PICU patients.

Conclusions: Iatrogenic exposure to DEHP metabolites during intensive care was independently and robustly associated with the important attention deficit observed in children 4 years after critical illness. Clinicaltrials.gov identifier: NCT00214916.

Keywords: Attention; Critical illness; Neurocognitive development; PICU; Phthalate; Plasticizers; Sepsis.

References

    1. Food Chem Toxicol. 2002 Oct;40(10):1499-506
    1. J Thorac Cardiovasc Surg. 1983 Dec;86(6):823-31
    1. Environ Health Perspect. 2014 Sep;122(9):998-1005
    1. Ann Thorac Surg. 2007 Apr;83(4):1425-30
    1. Regul Toxicol Pharmacol. 2016 Apr;76:209-10
    1. Toxicol Lett. 2009 Aug 25;189(1):40-7
    1. Environ Health Perspect. 2010 Apr;118(4):565-71
    1. Lancet Oncol. 2012 Mar;13(3):256-64
    1. Lancet. 2009 Feb 14;373(9663):547-56
    1. Early Hum Dev. 2014 Sep;90(9):477-85
    1. Stat Med. 2003 Feb 28;22(4):559-71
    1. Int J Pharm. 2000 Dec 4;210(1-2):109-15
    1. Biol Psychiatry. 2009 Nov 15;66(10 ):958-63
    1. Int J Androl. 2006 Feb;29(1):155-65; discussion 181-5
    1. Open Heart. 2015 Oct 29;2(1):e000255
    1. J Thorac Cardiovasc Surg. 2002 Jan;123(1):110-8
    1. JAMA. 2012 Oct 24;308(16):1687-8
    1. Environ Health Perspect. 2012 Feb;120(2):290-5
    1. Environ Res. 2014 Jan;128:64-9
    1. JAMA. 2012 Oct 24;308(16):1641-50
    1. Sci Total Environ. 2012 Aug 15;432:357-64
    1. Neural Plast. 2004;11(1-2):59-76
    1. Endocrinology. 2015 Jun;156(6):1941-51
    1. Endocrinology. 2013 Nov;154(11):3955-6
    1. Environ Int. 2013 Sep;59:344-53
    1. J Int Neuropsychol Soc. 2005 Mar;11(2):173-83
    1. Toxicol Lett. 2011 Feb 25;201(1):34-41
    1. Environ Int. 2015 Aug;81:64-72
    1. Environ Health Perspect. 2005 Sep;113(9):1222-5
    1. Neuroimage. 2005 Jun;26(2):471-9
    1. Circulation. 1999 Aug 3;100(5):526-32
    1. N Engl J Med. 2015 Feb 26;372(9):796-7
    1. N Engl J Med. 1995 Mar 2;332(9):549-55
    1. BMJ. 1994 Oct 1;309(6958):837-41
    1. Pediatrics. 2009 Dec;124(6):e1064-71
    1. Community Genet. 1998;1(1):12-7
    1. Expert Rev Neurother. 2008 Apr;8(4):611-25
    1. Psychol Med. 2015 Jun;45(8):1601-12
    1. Environ Health Perspect. 2006 Sep;114(9):1424-31

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner